GregorySMontgomeryMD

Pediatric Pulmonology • Indianapolis, IN

Chronic Lung Disease of Prematurity and Infancy, Pediatric Bronchoscopy, Pediatric Interstitial Lung Disease Pulmonology

Professor of Clinical Pediatrics; Medical Director, Pediatric PH Center of Comprehensive Care; Director, Rare Lung Disease Program; Director, Pulmonary Inpatient Services

Join to view full profile

Dr. Montgomery is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Montgomery's full profile

Already have an account?

Office
705 Riley Hospital Dr
Pulmonary MSA
Indianapolis, IN 46202
Phone+1 317-948-7208

Fax+1 317-944-5791
Is this information wrong?

Summary

Dr. Gregory Montgomery is a pediatric pulmonologist in Indianapolis, IN and is affiliated with multiple hospitals in the area, including Riley Hospital for Children at Indiana University Health, Indiana University Health North Hospital, and Eskenazi Health. He received his medical degree from Indiana University School of Medicine and has been in practice 19 years. He specializes in pediatric pulmonary hypertension, chronic lung disease of prematurity and infancy, pediatric flexible bronchoscopy, pediatric interstitial and rare lung disease and pediatric exercise physiology.

Clinical Expertise

Pulmonary hypertension, Bronchopulmonary dysplasia, Pediatric bronchoscopy, Pediatric exercise physiology, General pulmonology, Pediatric interstitial lung disease

Education & Training

University of ColoradoFellowship, Pediatric Pulmonology, 2002 - 2005
University of MinnesotaChief Residency, Pediatrics, 2001 - 2002
University of MinnesotaResidency, Pediatrics, 1999 - 2001
University of MinnesotaInternship, Pediatrics, 1998 - 1999
Indiana University School of MedicineClass of 1998
Indiana UniversityBS, Biology, 1990 - 1994

Certifications & Licensure

IN State Medical License 2005 - 2025
CO State Medical License 2002 - 2005
MN State Medical License 2001 - 2003
American Board of Pediatrics Pediatric Pulmonology

Awards, Honors, & Recognition

Indianapolis Top Doctor Castle Connelly, 2016-2023

Clinical Trials

Antimicrobial Resistance in Cystic Fibrosis (CF) Start of enrollment: 2006 Mar 01
Completed
Cystic Fibrosis Foundation (CFF) Biomarkers of Exacerbation Start of enrollment: 2007 Dec 01
Completed
MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis Start of enrollment: 2010 Nov 01
Completed
Phase 3
Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients Start of enrollment: 2011 Jan 01
Completed
Phase 3
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension Start of enrollment: 2012 Jul 17
Completed
Phase 1, Phase 2
G551D Observational Study- Expanded to Additional Genotypes and Extended for Long Therm Follow up (GOAL-e2) Start of enrollment: 2014 Jan 01
Completed
Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation Start of enrollment: 2013 Jan 01
Completed
Phase 3
A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation Start of enrollment: 2013 Apr 01
Completed
Phase 3
An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis Start of enrollment: 2013 May 01
Completed
Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation Start of enrollment: 2013 Jul 01
Completed
Phase 3
A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis Start of enrollment: 2013 Oct 01
Completed
Phase 3
Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation Start of enrollment: 2013 Dec 01
Completed
Phase 3
A Two-Part Multicenter Prospective Longitudinal Study of CFTR-dependent Disease Profiling in Cystic Fibrosis (PROSPECT) Start of enrollment: 2015 Mar 01
Completed
A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation Start of enrollment: 2015 Aug 01
Completed
Phase 3
Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor Start of enrollment: 2015 Aug 01
Completed
Phase 3
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation Start of enrollment: 2016 Jun 02
Completed
Phase 3
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del Start of enrollment: 2016 May 01
Completed
Phase 3
A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH) Start of enrollment: 2017 Oct 24
Recruiting
Phase 3
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF) Start of enrollment: 2016 Nov 01
Completed
Phase 3
A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation Start of enrollment: 2017 May 12
Completed
Phase 3
A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation Start of enrollment: 2017 Aug 16
Completed
Phase 3
A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD) Start of enrollment: 2019 Dec 03
Completed
Phase 3
A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension Start of enrollment: 2020 Jan 16
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Diagnostic yield of bronchoscopy in children with leukemia or post hematopoietic stem cell transplant.
Livia Georgescu, April L Rahrig, Gregory Montgomery, Courtney M Rowan> ;Pediatric Pulmonology. 2024 Jan 1
3 citations
The US national registry for childhood interstitial and diffuse lung disease: Report of study design and initial enrollment cohort.
Rebekah J Nevel, Gail H Deutsch, Daniel Craven, Robin Deterding, Martha P Fishman, Jennifer A Wambach, Alicia Casey, Katie Krone, Deborah R Liptzin, Michael G O'Connor...> ;Pediatric Pulmonology. 2023 Jul 4
Cystic fibrosis.
Gregory S Montgomery, Michelle Howenstine> ;Pediatrics in Review. 2009 Aug 1
2 citations
Adjusting ventilator settings to avoid air trapping in extremely premature infants reduces the need for tracheostomy and length of stay.
Ibrahim Sammour, Steven M Conlon, Sarah E Bauer, Gregory S Montgomery, A Ioana Cristea, Rebecca S Rose> ;Frontiers in Pediatrics. 2022 Jan 1
1 citations
Wheezing in preterm infants and children.
Eli Rhoads, Gregory S. Montgomery, Clement L. Ren> ;Pediatric Pulmonology. 2021 Feb 12
ATS Core Curriculum 2020. Pediatric Pulmonary Medicine
Jane E. Gross, Michael Y. McCown, Caroline Okorie, Lara C. Bishay, Fei J. Dy, Jordan S. Rettig, Christopher D. Baker, John R. Balmes, Andrew T. Barber, Sourav Bose, Al...> ;ATS Scholar. 2020 Dec 30
6 citations
Lung biopsy in children's interstitial and diffuse lung disease: Does it alter management?
Niloufar Hafezi, Mark A. Heimberger, Kyle A. Lewellen, Thomas K. Maatman, Gregory S. Montgomery, Troy A. Markel> ;Pediatric Pulmonology. 2020 Feb 10
2 citations
Combination therapy for severe portopulmonary hypertension in a child allows for liver transplantation.
Ryan M. Serrano, Girish Subbarao, Richard S. Mangus, Greg Montgomery, Michael Johansen> ;Pediatric Transplantation. 2019 Aug 1
Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma.
Stempel DA, Szefler SJ, Pedersen S, Zeiger RS, Yeakey AM, Lee LA, Liu AH, Mitchell H, Kral KM, Raphiou IH, Prillaman BA, Buaron KS, Yun Kirby S, Pascoe SJ, VESTRI Inve...> ;The New England journal of medicine.
164 citations
Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study
Margaret Rosenfeld, Claire E. Wainwright, Mark Higgins, Linda T Wang, Charlotte M. McKee, Daniel Campbell, S. Tian, Jennifer Schneider, Steve Cunningham, Jane C. Davie...> ;The Lancet. Respiratory Medicine. 2018 Jul 1
5 citations
Efficacy, cost effectiveness, and sustainability of a pediatric high risk asthma clinic
Nadia L. Krupp, Andrea Weist, Cindy Fiscus, James E. Slaven, Andrew Harner, Gregory S. Montgomery, Michelle S. Howenstine> ;Pediatric Pulmonology. 2018 May 1
47 citations
Association of Antibiotics, Airway Microbiome, and Inflammation in Infants with Cystic Fibrosis.
Jessica E. Pittman, Kristine M. Wylie, Kathryn Akers, Gregory A. Storch, Joseph Hatch, Jane Quante, Katherine B Frayman, Nadeene Clarke, Miriam Davis, Stephen M. Stick...> ;Annals of the American Thoracic Society. 2017 Sep 29
19 citations
Multifaceted quality improvement initiative to decrease pediatric asthma readmissions
Nadia L. Krupp, Cindy Fiscus, Russell Webb, Emily C. Webber, Teresa Stanley, Rebecca S. Pettit, Ashley Davis, Judy Hollingsworth, Deborah Bagley, Marjorie S. Mccaskey,...> ;The Journal of Asthma. 2017 Feb 27
Preterm respiratory disease in the modern era: the value of cohort studies.
Gregory S. Montgomery, Stephanie D. Davis> ;Thorax. 2017 Aug 1
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.
Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A,...> ;The New England journal of medicine. 2015-05-17
42 citations
Effect of treatment of cystic fibrosis pulmonary exacerbations on systemic inflammation
Scott D. Sagel, Valeria Thompson, James F. Chmiel, Gregory S. Montgomery, Samya Z. Nasr, Elizabeth Perkett, Milene T. Saavedra, Bonnie Slovis, Margaret M. Anthony, Peg...> ;Annals of the American Thoracic Society. 2015 May 12
82 citations
Official American Thoracic Society Technical Standards: Flexible Airway Endoscopy in Children
Albert Faro, Robert E. Wood, Michael S. Schechter, Albin Leong, Eric Wittkugel, Kathy Abode, James F. Chmiel, Cori L. Daines, Stephanie D. Davis, Ernst Eber, Charles B...> ;American Journal of Respiratory and Critical Care Medicine. 2015 May 1
6 citations
Why exercise capacity does not improve after pulmonary valve replacement.
Lauren E. Sterrett, Eric S. Ebenroth, Christina Query, Jason G. Ho, Gregory S. Montgomery, Roger A. Hurwitz, Fitsum Baye, Marcus S. Schamberger> ;Pediatric Cardiology. 2014 Jul 3
10 citations
An Infant With Pulmonary Interstitial Glycogenosis: Clinical Improvement Is Associated With Improvement in the Pulmonary Diffusion Capacity
Zarmina Ehsan, Gregory S. Montgomery, Christina Tiller, Jeffrey Kisling, Daniel V. Chang, Robert S. Tepper> ;Pediatric Pulmonology. 2014 Mar 1
5 citations
Propranolol in the treatment of upper airway hemangiomas.
Lauren C.Anderson de Moreno, Bruce H. Matt, Gregory S. Montgomery, Young Jee Kim> ;Ear, Nose, & Throat Journal. 2013 Apr 1
7 citations
Pulmonary Limitation to Exercise After Repair of D-Transposition of the Great Vessels: Atrial Baffle Versus Arterial Switch
Lauren E. Sterrett, Eric S. Ebenroth, Gregory S. Montgomery, Marcus S. Schamberger, Roger A. Hurwitz> ;Pediatric Cardiology. 2011 Jun 4
7 citations
Acid-base disorders.
Mara Nitu, Greg Montgomery, Howard Eigen> ;Pediatrics in Review. 2011 Jun 1
23 citations
Randomized Controlled Trial of Fish Oil and Montelukast and Their Combination on Airway Inflammation and Hyperpnea-Induced Bronchoconstriction
Sandra Tecklenburg-Lund, Timothy D. Mickleborough, Louise A. Turner, Alyce D. Fly, Joel M. Stager, Gregory S. Montgomery> ;Plos One. 2010 Oct 18
9 citations
Effect of fish oil-derived omega-3 polyunsaturated Fatty Acid supplementation on exercise-induced bronchoconstriction and immune function in athletes.
Timothy D. Mickleborough, Martin R. Lindley, Gregory S. Montgomery> ;The Physician and Sportsmedicine. 2008 Jan 1
53 citations
Eicosapentaenoic acid is more effective than docosahexaenoic acid in inhibiting proinflammatory mediator production and transcription from LPS-induced human asthmatic ...
Timothy D. Mickleborough, Sandra Tecklenburg, Gregory S. Montgomery, Martin R. Lindley> ;Clinical Nutrition. 2009 Feb 1
Join now to see all

Books/Book Chapters

Pediatric Respiratory Medicine
Chapter: Thoracic tumors
Page 1025 - 1030Deterding RR, Montgomery GSEditors: Taussig L, Landau L.Mosby/Elsevier, Philadelphia, PAEdition 2nd,2008

Authored Content

Pediatric Pulmonologists Say Kids Should Mask UpAugust 2021

Press Mentions

She dreamed of building rockets. What's happened since Annie's death will help others soarApril 15th, 2024
“He’s a happy boy … when he’s not having a sickle cell flare-up”September 26th, 2023
Riley Pediatric Pulmonary Hypertension program receives PHA accreditation as PHCCJune 1st, 2023
Join now to see all

Committees

Physician Member, Pulmonary Hypertension Association PHPN Symposium Planning Committee 2020 - Present
Data Monitoring Committee Member, CF Foundation Therapeutics Data & Safety Monitoring Board 2011 - 2022